J&J Separates U.S. OTCs In "Unorthodox" Reorg To Get McNeil Back On Track
This article was originally published in The Pink Sheet Daily
Executive Summary
The reorganization separates the U.S. OTC business - McNeil Consumer Healthcare - from the other consumer divisions "in order to give focused attention to quality and compliance, and the critical task of restoring" McNeil brands.
You may also be interested in...
J&J Taps Gorsky To Be Its Next CEO
Alex Gorsky was one of two internal candidates who had been vying for the position, which will become available as William Weldon yields the position on April 26.
J&J Taps Gorsky To Be Its Next CEO
Alex Gorsky was one of two internal candidates who had been vying for the position, which will become available as William Weldon yields the position on April 26.
J&J Takes The Lead In Settling SEC/DoJ Foreign Corrupt Practices Act Probe
Johnson & Johnson agreed to pay $70 million to resolve charges by the Securities and Exchange Commission and the Department of Justice that the company bribed doctors in several European countries to order or prescribe its products in violation of the Foreign Corrupt Practices Act